Capital Flow Monitor · Sponsors · CIK 1882782
Odyssey Therapeutics, Inc.
51 SLEEPER STREET, BOSTON, MA, 02210 · 617-865-9628
Biotechnology · Corporation· inc. DELAWARE true 2021
Fit score
—
Offering
$214.0M
Sold
$214.0M
% sold
100.0%
Investors
55
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-12-04 | D ·current | 506(b) | $214.0M | $214.0M | 100.0% | 55 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Gary D. Glick — Executive Officer / Director, Boston, MA
-
Carl Gordon — Director, Boston, MA
2 other raises
- Star Therapeutics LLC $125.0M of $125.0M · 100.0%
- Avenzo Therapeutics, Inc. $47.2M of $75.0M · 63.0%
-
Jill Carroll — Director, Boston, MA
1 other raise
- AirNexis Therapeutics, Inc. $62.0M of $200.0M · 31.0%
- Valerie Odegard — Director, Boston, MA
-
Nan Li — Director, Boston, MA
2 other raises
- Dimension Capital III, L.P. $0 of $750.0M · 0.0%
- Fiveonefour Labs Inc. $10.8M of $10.8M · 100.0%
- Jeffrey Leiden — Director, Boston, MA
-
Paulina Hill — Director, Boston, MA
1 other raise
- NextPoint Therapeutics, Inc. $33.7M of $48.7M · 69.2%
-
Timothy Walbert — Director, Boston, MA
1 other raise
- Mirum Pharmaceuticals, Inc. $68.5M of $68.5M · 100.0%
- lan F. Smith — Director, Boston, MA
-
Shelley Chu — Director, Boston, MA
2 other raises
- Triana Biomedicines, Inc. $120.1M of $120.1M · 100.0%
- Enlaza Therapeutics, Inc. $15.0M of $15.0M · 100.0%
- Ksenija Pavletic — Director, Boston, MA
- Carolyn Ng — Director, Boston, CA
- Nia Tatsis — Director, Boston, MA
- Jason Haas — Executive Officer, Boston, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.